Certara's Simcyp Simulator Receives EMA Qualification for PBPK Modeling
ByAinvest
Monday, Aug 4, 2025 2:02 am ET1min read
CERT--
The EMA qualification covers three context-of-use scenarios (COUs) that span six CYP enzymes and two inhibition mechanisms, significantly reducing the number of clinical studies required. This development aligns with the industry's shift towards model-informed drug development (MIDD), where computational models replace certain clinical studies [2].
The qualification is a result of a rigorous, multi-year collaborative engagement between Certara and the EMA. This collaboration underscores the scientific validity of Certara's platform and positions it with a substantial competitive advantage in the biosimulation market [1].
From a regulatory perspective, this development simplifies the drug submission process, potentially reducing development costs and accelerating time-to-market for new drugs. As regulatory bodies increasingly accept simulation-based evidence, Certara's first-mover advantage could strengthen its market position and expand its customer base among pharmaceutical developers seeking to streamline their regulatory submission processes [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Certara+Simcyp%C2%AE+Simulator+Becomes+First+and+Only+Software+Platform+to+Receive+EMA+Qualification+Opinion+for+PBPK+Modeling/25138406.html
[2] https://www.stocktitan.net/news/CERT/certara-simcyp-simulator-becomes-first-and-only-software-platform-to-xvfac7y2o45k.html
Certara's Simcyp Simulator has become the first and only software platform to receive European Medicines Agency (EMA) qualification for PBPK modeling. This recognition allows sponsors to use the platform in regulatory submissions across the EU to assess drug-drug interaction risk without re-establishing credibility. The qualification covers various scenarios and significantly reduces the number of clinical studies required.
Certara, Inc., a global leader in biosimulation, has achieved a significant milestone with the European Medicines Agency (EMA) qualifying its Simcyp® Simulator for use in regulatory submissions across the EU. This recognition marks the first and only software platform to receive such qualification for physiologically-based pharmacokinetic (PBPK) modeling [1]. The qualification allows sponsors to assess drug-drug interaction (DDI) risk without needing to re-establish the platform's credibility for each regulatory submission [2].The EMA qualification covers three context-of-use scenarios (COUs) that span six CYP enzymes and two inhibition mechanisms, significantly reducing the number of clinical studies required. This development aligns with the industry's shift towards model-informed drug development (MIDD), where computational models replace certain clinical studies [2].
The qualification is a result of a rigorous, multi-year collaborative engagement between Certara and the EMA. This collaboration underscores the scientific validity of Certara's platform and positions it with a substantial competitive advantage in the biosimulation market [1].
From a regulatory perspective, this development simplifies the drug submission process, potentially reducing development costs and accelerating time-to-market for new drugs. As regulatory bodies increasingly accept simulation-based evidence, Certara's first-mover advantage could strengthen its market position and expand its customer base among pharmaceutical developers seeking to streamline their regulatory submission processes [2].
References:
[1] https://www.streetinsider.com/Globe+Newswire/Certara+Simcyp%C2%AE+Simulator+Becomes+First+and+Only+Software+Platform+to+Receive+EMA+Qualification+Opinion+for+PBPK+Modeling/25138406.html
[2] https://www.stocktitan.net/news/CERT/certara-simcyp-simulator-becomes-first-and-only-software-platform-to-xvfac7y2o45k.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet